Site Search
Professionals 112 results
Capabilities 42 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Practice Area
As society and business become even more digitalized, technology and intellectual property (IP) have become key focal points for businesses. Our Technology Antitrust Group combines the cross-practice and cross-office experience of our lawyers to assist clients in successfully navigating the dynamic convergence of technology, antitrust, and IP law. We understand the challenges presented by the ever-changing digital landscape and are committed to providing our clients with tailored solutions to address their specific needs.
Practice Area
Trade Secrets, Non Competes & Restrictive Covenants
Theft of trade secrets and other confidential information occurs all too frequently in today’s global, highly mobile, and competitive marketplace. In the course of advising clients, we have developed comprehensive, yet scalable, strategies for both mitigating against and responding to issues along the trade secrets protection spectrum, including helping position clients proactively before trade secrets theft occurs.
Experience 100 results
Experience
|April 11, 2025
Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering
Experience
|April 10, 2025
Titan Acquisition Corp Announces Closing of $276,000,000 Initial Public Offering
Experience
|January 29, 2025
Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering
Insights & News 690 results
Sponsorship
|May 28, 2025
Winston & Strawn Sponsors SBIA’s 2025 Midwest Deal Summit
Winston & Strawn is proud to be an elite sponsor for the Small Business Investor Alliance’s (SBIA) 2025 Midwest Deal Summit on May 28-29, 2025, in Chicago.
Seminar/CLE
|May 13, 2025
2025 Health Care & Life Sciences Summit
Winston & Strawn is pleased to host its fifth annual Health Care & Life Sciences Summit. Clients and friends of the firm are invited to join us to network with peers and gain insights from industry leaders and legal experts. The summit will take place live at our Chicago office, and CLE-eligible recordings of the Summit’s sessions will be available shortly following the event.
In the Media
|May 5, 2025
|1 Min Read
Brad Mandel Discusses Potential Impacts of Tariffs on the Secondary Market with SecondaryLink
Winston & Strawn partner Brad Mandel spoke with SecondaryLink to provide his insights on how tariff policies are set to influence the secondary market. When President Trump took office in January, markets were coming off highs, with the S&P 500 rallying 23% in 2024 and the secondary market reaching an estimated $162 billion. Trump’s tariff announcements have since triggered swings in public equities and heightened volatility, sparking various questions in the secondary market. In the Q&A, Brad touched on topics including how the tariffs will impact secondary market volume and fundraising, seller behavior and motivations, strategy pricing and demand shifts, and more.
Other Results 33 results
Site Content
What Is the Price Range in an IPO?
The price range is a proposed price per share range for the IPO within which investors can bid for shares and which is often printed on the cover page of a preliminary prospectus. The price range has a minimum price, known as the floor price, and a maximum price, known as the cap price.
Site Content
Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) to provide an abbreviated pathway for biosimilars to gain FDA approval through submission of an abbreviated Biologics License Application (aBLA).
Site Content
Dilution refers to the reduction in an existing shareholder’s ownership percentage of a company when the company issues additional shares. Dilution in an IPO results from a disparity between the public offering price in an IPO and the effective cash cost to persons who acquired shares prior to the IPO. Dilution is disclosed in the registration statement in a dilution table.